Prolight Diagnostics AbNGM: PRLD

PRLD: Losses increased amid product development, but funding and patent milestones support 2027 launch

· Issued by Prolight Diagnostics Ab

Operating losses widened as product development accelerated, but liquidity was bolstered by a fully subscribed SEK 100.3 million rights issue. Key patents were granted, and the Psyros system prototype was showcased, with commercialization now targeted for 2027.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.